Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2021 Aug;17(8):1265-1276.
doi: 10.1002/alz.12293. Epub 2021 Feb 1.

Generalizability of findings from a clinical sample to a community-based sample: A comparison of ADNI and ARIC

Affiliations
Free PMC article
Comparative Study

Generalizability of findings from a clinical sample to a community-based sample: A comparison of ADNI and ARIC

Kan Z Gianattasio et al. Alzheimers Dement. 2021 Aug.
Free PMC article

Abstract

Introduction: Clinic-based study samples, including the Alzheimer's Disease Neuroimaging Initiative (ADNI), offer rich data, but findings may not generalize to community-based settings. We compared associations in ADNI to those in the Atherosclerosis Risk in Communities (ARIC) study to assess generalizability across the two settings.

Methods: We estimated cohort-specific associations among risk factors, cognitive test scores, and neuroimaging outcomes to identify and quantify the extent of significant and substantively meaningful differences in associations between cohorts. We explored whether using more homogenous samples improved comparability in effect estimates.

Results: The proportion of associations that differed significantly between cohorts ranged from 27% to 34% across sample subsets. Many differences were substantively meaningful (e.g., odds ratios [OR] for apolipoprotein E ε4 on amyloid positivity in ARIC: OR = 2.8, in ADNI: OR = 8.6).

Discussion: A higher proportion of associations differed significantly and substantively than would be expected by chance. Findings in clinical samples should be confirmed in more representative samples.

Keywords: Alzheimer's Disease Neuroimaging Initiative; Alzheimer's disease; Atherosclerosis Risk in Communities; dementia; generalizability.

PubMed Disclaimer

Conflict of interest statement

Declaration of interest

KZG, EEB, JW, MLM, EAS, MEG, MMG, and MCP have nothing to declare

RFG is an associate editor for the journal Neurology

DFW has related grants from NIH and have previously received contracts through John Hopkins University from Roche and Lundbeck for dementia imaging in 2019.

TM, DJC have related grants from NIH

Figures

Figure 1.
Figure 1.
Heatmap of P-values for statistical significance in differences across ADNI and ARIC estimated associations between risk factors and cognitive test/imaging outcomes, and between imaging outcomes and cognitive test outcomes; limited to associations with p<0.05 statistical significance independently in at least one study NA: Association not applicable to sample I: Association not significant to p<0.05 in either cohort
Figure 2.
Figure 2.
Heatmap of percentage differences in point estimates of associationsa between risk factors and cognitive test/imaging outcomes, and between imaging outcomes and cognitive test outcomes; limited to associations with p<0.05 statistical significance independently in at least one study a Percentage difference relative to ARIC estimates, computed as ∣ARIC estimate – ADNI estimate∣/∣ARIC estimate∣ NA: Association not applicable to sample I: Association not significant to p<0.05 in either cohort
Figure 3.
Figure 3.
Comparison of estimated associations in ADNI vs. in ARIC using all available observations a that are significant to p<0.05 in at least one cohort; continuous outcomes a for associations involving SUVR, this excludes observations of participants with dementia
Figure 4.
Figure 4.
Comparison of estimated associations in ADNI vs. in ARIC using all available observations a that are significant to p<0.05 in at least one cohort; binary outcomes a for associations involving SUVR, this excludes observations of participants with dementia b MMSE (score < 25) c boston naming (score < 25) d SUVR (cohort cut-off)

Similar articles

Cited by

References

    1. Kukull WA, Ganguli M. Generalizability: The trees, the forest, and the low-hanging fruit. Neurology. 2012;78(23):1886–1891. doi:10.1212/WNL.0b013e318258f812 - DOI - PMC - PubMed
    1. Alzheimer’s Disease Neuroimaging Initiative. Study Design. Alzheimer’s Disease Neuroimaging Initiative. http://adni.loni.usc.edu/study-design/. Published 2017. Accessed September 24, 2019.
    1. Veitch DP, Weiner MW, Aisen PS, et al.Understanding disease progression and improving Alzheimer’s disease clinical trials: Recent highlights from the Alzheimer’s Disease Neuroimaging Initiative. Alzheimer’s Dement. 2019;15(1):106–152. doi:10.1016/j.jalz.2018.08.005 - DOI - PubMed
    1. Weiner MW, Veitch DP, Aisen PS, et al.Recent publications from the Alzheimer’s Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials. Alzheimer’s Dement. 2017;13(4):e1–e85. doi:10.1016/j.jalz.2016.11.007 - DOI - PMC - PubMed
    1. Petersen RC, Aisen PS, Beckett LA, et al.Alzheimer’s Disease Neuroimaging Initiative (ADNI): Clinical characterization. Neurology. 2010;74(3):201–209. doi:10.1212/WNL.0b013e3181cb3e25 - DOI - PMC - PubMed

Publication types

Substances